Formula Pharma by Mark JC Nuijten.

work info

a2m, partner of Minerva Network, develops multicountry health economic models for its clients all over the world: cost-effectiveness models and budget impact models.

The models by a2m successfully contributed to positive reimbursement decisions by health authorities in many countries. read more

a2m has established strategic global collaborations with key local market access and reimbursement experts in the key European markets, as well as the US, Canada and Japan for preparation of reimbursement dossiers (e.g. TLV in Sweden, SMC in Scotland, RIZIV in Belgium, and CVZ in The Netherlands).

Notes

The true prices of drugs

Just published
Evaluation and valuation of innovative medicinal products Nuijten MJC, Vis J. J Rare Dis Res Treat. (2016) 2(1): 1-11

This innovative concept can support the pricing strategy of your "expensive" products in pricing negotiations with health authorities. In this paper we are combining health economic and market access concepts with principles of business valuation to justify prices for drugs, which are not cost-effective. It may provide an argument to counterbalance increasing subjective complaints by health authorities that drug prices are too excessive and not justified. Especially for orphan drugs and biologicals, this concept is relevant and can provide a solution. Although there is no formal legal framework for this concept (yet!), it may already be useful in informal price negotiations with health authorities. As the Dutch Minister of Health proposes joint price negotiations with Netherlands and Belgium for drugs with an ICER far beyond the threshold (larger than euro 100,000/QALY). In these discussions, this approach may be used by pharma or biotech companies to justify the drug objectively and limit the discount of the drug price in these negotiations. This approach may also be relevant for price negotiations in Germany, where the ICER is not formally used.

You can get the original paper by sending an email to mark@a2m.nl.

De echte prijs van geneesmiddelen


Zojuist gepubliceerd 
Evaluation and valuation of innovative medicinal products Nuijten MJC, Vis J. J Rare Dis Res Treat. (2016) 2(1): 1-11

Dit innovatieve concept kan de pricing strategie van "dure" geneesmiddelen in ondersteunen in prijsonderhandelingen met de overheid en verzekeraars.

In dit artikel hebben we de concepten van gezondheidseconomie gecombineerd met financiële waarderingsmethodologie om de prijzen van zogenaamde “dure”geneesmiddelen objectief te onderbouwen. Het kan een argument zijn tegen de toenemende subjectieve klachten door artsen en overheid dat de prijzen van veel nieuwe innovatieve geneesmiddelen te hoog en niet gerechtvaardigd zijn. Speciaal voor weesgeneesmiddelen en biologicals kan dit concept relevant zijn en een onderbouwing van de prijs geven. Hoewel er (nog!) geen formeel juridische kader voor dit concept is, kan het al nuttig zijn bij informele prijsonderhandelingen met de overheid en verzekeraars. De Nederlandse minister van Volksgezondheid stelt gezamenlijke prijsonderhandelingen met België voor met farmaceutische bedrijven voor geneesmiddelen met een ICER ("incrementele cost-effectiveness ratio" doelmatigheid die veel hoger is dan de drempel (groter dan euro 100.000 / QALY). In deze besprekingen, kan onze aanpak worden gebruikt door farmaceutische bedrijven om de prijs van een geneesmiddel objectief te rechtvaardigen en daardoor de korting van de prijs van het geneesmiddel in deze onderhandelingen te beperken. Deze aanpak kan ook relevant voor zijn voor prijsonderhandelingen met overheden in Duitsland, waar de ICER niet officieel gebruikt wordt.

U kunt een verzoek voor het originele artikel sturen naar: mark@a2m.nl

A2M - Minerva in Vienna at ISPOR

Ars Accessus Medica (a2m) partner of Minerva Network, is presented by Dr. Mark Nuijten at the  ISPOR 19th Annual European Congress, 29 October - 2 November 2016, Vienna. You can meet him at the Minerva booth. A2M wishes you a very good ISPOR congress and looks forward to meet you.

ISPOR Vienna

A2M is well presented at ISPOR 19th Annual European Congress, 29 October - 2 November 2016, Vienna, Austria with the following presentations by Dr. Mark Nuijten covering standard cost-effectiveness analyses, nutritioneconomics and financial valuation for medical innovatiion.

UK COST-EFFECTIVENESS ANALYSIS FOR MANAGEMENT OF CMV DISEASE IN PATIENTS POST ALLOGENEIC STEM CELL TRANSPLANTATION WITH A NOVEL ADOPTIVE T CELL THERAPY 


EVALUATION OF METHODOLOGICAL VARIATIONS IN THE EVENT SIMULATION APPROACHES OF PUBLISHED HEALTH ECONOMIC MODELS IN OBESITY PREVENTION AND THERAPY

FOOD FOR THOUGHT (BUT NOT TOO MUCH) FOR HEALTH ECONOMIC ANALYSES OF NUTRITIONAL INTERVENTIONS IN OBESITY

ECONOMIC VALUATION OF ULTRA-INNOVATIVE DRUGS FROM A BROADER PERSPECTIVE

Evaluation and valuation of ultra-innovative drugs: a new concept

Mark Nuijten and Prof. Jan Vis published an interesting policy paper “ECONOMIC VALUATION OF ULTRA-INNOVATIVE DRUGS: A BROADER PERSPECTIVE”. July - August 2016 (2016). Value & Outcomes Spotlight.

Presentation of NICE model at European Hematology Association

Results of a study by Mark Nuijten, Catherine Kielar, Holger Müller and Carl Peggs were presented at the 21th congress of the European Hematology Association (EHA), June 9 - 12, 216 in Copenhagen, Denmark: COST-EFFECTIVENESS ANALYSIS OF A DIRECTLY SELECTED CMV-SPECIFIC T-CELL THERAPY FOR MANAGEMENT OF CMV DISEASE IN PATIENTS POST ALLOGENEIC STEM CELL TRANSPLANTATION: A UK ANALYSIS.

Valuation tool for biotechnology

Dr. Mark Nuijten (A2M) gave a lecture on “VALUATION OF HEALTHCARE INNOVATION: A DECISION ANALYTIC VALUATION MODEL FOR THE ASSESSMENT OF THE ECONOMIC VALUE OF AN INNOVATIVE MEDICINAL PRODUCT" for the European Biotechnology School, organized under auspices of the European Biotechnology Thematic Association (EBTNA) in Minsk, Belarius, May 29-June 3, 2016.xt

Valuation of innovation

Dr. Mark Nuijten (A2M) presented a new innovative tool for valuation of healthcare “VALUATION OF HEALTHCARE INNOVATION: A DECISION ANALYTIC VALUATION MODEL FOR THE ASSESSMENT OF THE ECONOMIC VALUE OF AN INNOVATIVE MEDICINAL PRODUCT" at the "European Biotechnology Congress 2016" in Riga, Latvia, on May 05-07, 2016.

Economics of obesity

Dr. Mark Nuijten presented “THE CHALLENGES OF HEALTH ECONOMIC ANALYSES OF NUTRITIONAL INTERVENTIONS IN OBESITY” at The European Obesity Summit, 1st and 4th of June 2016 in Gothenburg, Sweden.

Policy consultancy for Ministry of Health in The Netherlands 

A2M participated in consortium headed by APE to give policy guidance to the Dutch Ministry of Health in The Netherland on the reimbursement levels for outpatient drugs. January - May. 2016. (Verdiepingsonderzoek Geneesmiddelenvergoedingssysteem (GVS) Onderzoek in opdracht van het Ministerie van Volksgezondheid, Welzijn en Sport).

EURORDIS Multi-stakeholder Symposium in Brussels

Dr. Mark Nuijten was panellist at the Multi-stakeholder Symposium on Improving Patient Access to Rare Disease Therapies, EURORDIS. 24-25 February 2016 in Brussels, Belgium.

Annual Meeting DGO in Berlin

Dr Mark Nuijten presented at the Annual Meeting of the German Health Economic Association: “COST-EFFECTIVENESS ANALYSIS OF ORPHAN MEDICINAL PRODUCTS: AN ALTERNATIVE APPROACH” at the DGGÖ 2016. Berlin, March 14-15, 2016, Germany.

Lecture at EURORDIS in PARIS

Dr. Mark Nuijten gave 1-day lecture at EURORDIS in Paris. “THE APPROPRIATENESS OF THE COST PER QALY IN THE DECISION-MAKING PROCESS. THE VALUE OF INNOVATION IN HEALTH CARE”. Paris, France, November 24, 2015.

New joint publications a2m with Nestle and Danone

Two new interesting publications in nutritioneconomics by Dr Nuijten. The 15Th for Danone during a 5 years collaboration and a new publication for Nestlé Nutrition Institute in textbook.

MJC Nuijten. Health economics in medical nutrition: an emerging science. Part of a Nestle textbook. The importance of nutrition as an integral part of disease management.

Bruyère F, Buendia-Jiménez I,Lenoir-Wijnkoop I, M, Nuijten MJ. Urinary tract infections: Economical impact of water intake]. Prog Urol. 2015. Sep;25(10):590-7.

Economic impact of macrosomia

Dr Nuijten, CEO of a2m, is a pioneer in the field of nutrition-economics and has been the first classical health economist applying and developing health economic methodologies to nutritionals. He is founder of the ISPOR Special Interest Group “Nutrition Economics” and recently published his 15th scientific paper in nutrition economics, titled “Health economic modelling to assess short-term costs of maternal overweight, gestational diabetes and related macrosomia” in Frontiers in Pharmacology. This pilot study shows the initial results of ongoing health economic modelling research projects in this area.

International Market Access Update

A2M contributed this year successfully to various reimbursement dossiers for Scotland, Austria, Ireland, Wales, Belgium and The Netherlands. A2M developed the cost-effectiveness and budget impact analyses and provided guidance on the overall reimbursement and market access strategy.